Trypan Blue

Sold as Visionblue, Membraneblue. Every FDA application for this active ingredient.

As of Nov 13, 2026, FDA lists 2 applications for Trypan Blue (sold as Visionblue, Membraneblue), first approved Dec 16, 2004, with 0 new uses approved and 0 published complete response letters.

First approved: Dec 16, 2004
Applications: 2
New uses approved: 0
Complete response letters: 0

Clinical Trials

5 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all

Study	Phase	Status	Posted
Exploratory Evaluation of the BiP Inhibitor BPR001-615 in Primary Cells and the Diagnostic Value of Circulating BiP in Colorectal AdenocarcinomasColorectal Adenocarcinoma · Centre Hospitalier Universitaire de Nice	Not applicable	Recruiting	Sep 10, 2026
The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) StudyCorneal Transplant Failure, Corneal Endothelial Cell Loss · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	—	Recruiting	May 6, 2023
The Belgian Endothelial Surgical Transplant of the CorneaCorneal Edema, Corneal Endothelial Disorder · University Hospital, Antwerp	Not applicable	Active, not recruiting	Jun 29, 2022
Impact of ILM Peeling in RRD/ I-PeelRetinal Detachment · Berner Augenklinik	Not applicable	Active, not recruiting	Feb 23, 2021
Mechanical Properties of the Internal Limiting Membrane and Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted ChromovitrectomyMacular Edema · University Hospital, Basel, Switzerland	—	Recruiting	Dec 5, 2011

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Dec 16, 2004	VisionblueNDA 21670 · New molecular entity	Dorc	4	Marketed
Feb 20, 2009	MembraneblueNDA 22278 · New formulation or manufacturer	Dorc	3	Discontinued

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA